報價延遲最少15分鐘:2024/10/31 19:43 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8979 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.80/-0.16
|
|
企業價值
109.43M
|
| 資產負債 |
|
每股賬面淨值
1.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/10/31 19:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape. |